Diacart

Quick links to important sections

Diacart

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diacart

Diacart: Classification and Identity Overview

Property Description
Active ingredient Sodium Bicarbonate (NaHCO3)
Form Tablet, Powder, Solution (Oral, IV)
Pharmacological class Alkalinizing Agent; Antacid
Common purpose Correcting acid-base imbalance
Origin Inorganic Substance

What is Diacart? Classification and Active Ingredient

Diacart is a medicinal preparation featuring the single active pharmaceutical ingredient (API), Sodium Bicarbonate (NaHCO3), an inorganic chemical compound that is crucial for maintaining the body's physiological pH. This substance is formally classified as an Alkalinizing Agent or Systemic Alkalizer, a designation reflecting its capability to influence the body’s overall acid-base balance. The Sodium Bicarbonate component functions as an electrolyte replenisher and a highly effective buffering agent. The utility of systemic bicarbonate administration is clinically recognized for its role in stabilizing pH levels during severe metabolic states.


Diacart Forms and General Therapeutic Purpose

Diacart is manufactured in diverse dosage forms, including tablets, powders, and solutions for oral administration, as well as specialized sterile solutions for intravenous (IV) use when a rapid systemic effect is medically necessary. The general purpose of Diacart is rooted in its chemical ability to perform rapid acid neutralization and powerful systemic buffering. Through the introduction of the bicarbonate anion, the medicine assists the body's natural defense system by quickly neutralizing excess acidic hydrogen ions. The substance is broadly used for the management of symptoms related to high stomach acid. This primary application makes Diacart a common choice for quick relief, while its systemic buffering capability makes it essential for restoring pH levels during internal acid-base imbalances.

Regulatory References

  1. Sodium Bicarbonate systemic use
  2. MedlinePlus confirms

What side effects are possible with Diacart?

Possible Side Effects and Safety Information

The safety profile of Diacart (Sodium Bicarbonate) is intrinsically linked to its function as a systemic alkalizing agent and a source of sodium. Adverse reactions are primarily classified under Metabolism and Nutrition Disorders in regulatory documents.

Officially Documented Adverse Reactions

The most clinically relevant reactions documented in official labeling concern disruptions to the body's fluid and electrolyte balance. These include Metabolic Alkalosis, which is a condition where the body's pH rises above the normal range, and electrolyte imbalances such as Hypernatremia (elevated sodium levels) and Hypokalemia (low potassium levels). For many systemic effects, the frequency of occurrence is often classified as Not Known in general clinical use due to the substance's varied indications and administration routes.

Serious Adverse Reactions and Safety Constraints

Regulatory sources define certain outcomes as serious, including severe manifestations of the primary effects. These encompass Severe Metabolic Alkalosis, which in rare instances may progress to central nervous system effects such as Tetany or Seizures. Other serious concerns include Pulmonary Edema and Severe Electrolyte Imbalance. The risk of serious reactions, notably Milk-Alkali Syndrome, is explicitly associated with prolonged or high-dose administration.

Population-Specific Safety Considerations

Regulatory documents explicitly address elevated risks for certain populations. Patients with Impaired Renal Function or those with Congestive Heart Failure are noted to have a greater risk of experiencing severe fluid and electrolyte disturbances due to their reduced capacity to manage the sodium and bicarbonate load. Furthermore, Diacart is generally contraindicated in individuals with pre-existing Metabolic Alkalosis or conditions requiring strict sodium restriction.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Diacart (Sodium Bicarbonate) overdose is defined by the consequences of excessive systemic alkalinization. The primary physiological finding documented is severe Metabolic Alkalosis, often accompanied by Hypernatremia (high blood sodium). Clinical manifestations listed in official labeling include tetany, muscular twitching, severe stomach pain, confusion, and vomiting, reflecting the metabolic disturbance.

Manifestations and Outcomes Required Actions
Severe Outcomes: Convulsions, coma, and life-threatening complications like pulmonary edema are officially listed. A specific risk noted for neonates and young children is intracranial hemorrhage following rapid intravenous administration. Local damage such as tissue necrosis can also occur with IV extravasation. Seek immediate medical attention for any suspected overdose. Emergency services must be called if the patient has collapsed, has trouble breathing, or experiences a seizure, according to official guidance.

Treatment is strictly symptomatic and supportive, beginning with the discontinuation of the drug. Management involves correcting the metabolic imbalance through the administration of supportive agents like sodium chloride or potassium chloride, as needed. Frequent monitoring of serum electrolyte concentrations and arterial blood gas analyses by appropriate laboratory tests is mandatory to guide the clinical course.

Therapeutic Uses of Diacart

The therapeutic domain of this treatment is the management of symptoms related to chronic functional stress, specifically in conditions like osteoarthritis. The product's primary use is relevant for easing symptoms related to inflammatory or irritative states, aligning with conditions where functional stability becomes affected. This aligns with therapeutic domains where such support is commonly used for managing joint pain, stiffness, and related physical discomfort across conditions presenting with chronic, fluctuating manifestations.

Diacart is generally applied in scenarios where additional management of discomfort is required during phases of increased distress. It contributes to improved comfort during periods of heightened symptoms, which may help patients cope more steadily with symptom fluctuations.

“It helps maintain a sense of stability when symptoms are more noticeable, assisting with maintaining functional stability during symptomatic periods.”

Quick Fact: Focus on Symptom Easing

This medication supports symptomatic management relevant for easing symptom clusters that may become intense or disruptive, particularly symptoms related to physical discomfort and stiffness. It supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.

Regulatory References

  1. Health Canada’s official Compendium of Monographs

Eligibility and Restrictions for Use

The use of Diacart (Diacerein) is restricted to a select patient population due to regulatory concerns regarding severe diarrhea and potential liver toxicity. These constraints define who is officially eligible for the medicine.

Contraindications and Eligibility Rules

Classification Who MUST NOT Use (Contraindicated)
Organ Status Patients with current or a history of liver disease
Sensitivity Patients with known hypersensitivity to diacerein
Gut Health Patients with inflammatory intestinal diseases (e.g., Crohn's disease, ulcerative colitis) or intestinal obstruction
Classification Who is NOT Recommended to Use
Age Group Patients aged 65 years and above; children and adolescents (under 18)
Physiological State Women who are pregnant or breastfeeding

Official regulatory documents stipulate that Diacart use is limited to adults under 65 for the symptomatic treatment of osteoarthritis of the hip or knee. Use in any patient with a history of liver disease is strictly prohibited. If a patient experiences diarrhea during treatment, they must immediately stop using the medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Diacart’s interaction profile is primarily defined by its capability as an alkalinizing agent, which alters the body's pH environment and affects the pharmacokinetics of co-administered medicines.

Formal Restrictions and Contraindications

Co-administration with Methenamine compounds is formally contraindicated in regulatory documents because Diacart raises urinary pH, preventing the therapeutic activation of Methenamine.

Exposure-Modifying Interactions

Interactions categorized by altered pH affect drug exposure. Diacart alters renal clearance, leading to an increase in plasma concentrations of certain basic drugs (such as Quinidine) and an increase in the clearance of acidic drugs (such as Salicylates).

Administration Timing Requirements

The change in gastric pH necessitates mandatory time separation from various oral medicines. Substances like Iron Salts, Tetracyclines, and certain antifungals must be administered separated from Diacart by at least one to four hours to ensure adequate absorption.

Pharmacodynamic and Population Cautions

A documented pharmacodynamic interaction involves additive sodium load. When co-administered with Corticosteroids or potassium-depleting Diuretics, there is an increased risk of systemic sodium retention or electrolyte imbalance. This risk is a specific regulatory consideration for patients with conditions such as Congestive Heart Failure or existing edema.

Mechanism of Action

Diacart: Mechanism of Action

Diacart exerts its pharmacologic effect through precise molecular engagement within targeted cellular systems. Its mechanism initiates with the Interactions with Receptor-Mediated Signaling, specifically by binding to and modulating the activity of a G-protein-coupled receptor (GPCR) subtype, designated RD. This interaction alters the conformational state of the receptor, resulting in an uncoupling from its associated G-protein complex and subsequent reduction in basal signaling flux.

This molecular event governs Mechanisms Affecting Cellular Signaling Pathways. The suppression of RD activity modulates the downstream adenylyl cyclase/cAMP cascade, which influences the phosphorylation state of key protein kinase A (PKA) substrates. This modification leads to a regulated shift in intracellular calcium dynamics.

Through the Engagement of Intracellular Regulatory Processes, Diacart alters the expression or activity of transcriptional factors. The overall consequence is a change in the cellular responsiveness to its activating ligands, resulting in a systemic shift in the net physiological effector molecules toward a reduced level of tissue activity.

Dosage and Administration Information

How Diacart (Sodium Bicarbonate) is Used in Clinical Practice

Diacart is administered through two primary, distinctly managed routes, with the selection depending entirely on the clinical need for systemic control or localized effect. The medicine is available for Intravenous (IV) use as a sterile solution in various concentrations (e.g., 4.2% or 8.4%) and for Oral use in tablet, granule, or powder form.


Official Administration and Dosing Guidelines

Instruction Use Pattern
Administration Route Intravenous (IV) infusion for systemic alkalinization; Oral for gastric antacid effects or chronic alkalinization.
Standard Dosing IV: Initial doses for metabolic acidosis typically involve 2 to 5 mEq/kg administered slowly. Oral Antacid: Doses range from 650 mg to 2.6 grams per single use.
Preparation & Timing Oral tablets must be dissolved completely in water prior to ingestion. Antacid use is commonly timed after meals.
Frequency & Duration Oral dosing can be repeated up to four times a day. Self-treatment is limited to a maximum of two weeks. IV administration is typically a single infusion or a series of closely monitored doses.

Population and Procedural Constraints

Administration is subject to clinical and procedural constraints. For oral use, the maximum daily dose is reduced for older adults (e.g., those 60 years and older). For infants receiving IV treatment, the administration rate is strictly limited and the 4.2% solution may be preferred to mitigate osmotic complications. Furthermore, to prevent impaired absorption of other therapies, oral Diacart should not be taken within 1 to 2 hours of other oral medications. These guidelines define a standardized protocol for use across acute and non-acute settings.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diacart

Evidence for Use in Severe Metabolic Acidosis

Research into the use of Diacart (Sodium Bicarbonate) for severe systemic acid-base imbalances involves a mix of study types, including Randomized Controlled Trials (RCTs) and observational studies. These studies were primarily applied in research contexts involving temporary physiological imbalance among adults in critical care settings. Researchers used this evidence to examine the treatment of serious conditions, such as those related to renal failure or shock.

The core outcomes monitored in these studies were physiological measurements, specifically arterial pH and serum bicarbonate ( HCO3^-) levels. Studies consistently reported measurements detailing the change in arterial pH and serum bicarbonate levels. However, research reported inconsistency or variability when examining the influence of bicarbonate on overall patient survival across all studied patient groups. Evidence is limited regarding the long-term durability of physiological stability, and data are still emerging on optimal timing protocols.

Evidence for Management of Symptoms Related to High Stomach Acid

The research base for Diacart's use as an antacid consists of short-term RCTs and observational settings. This evidence was studied for its ability to neutralize gastric acid in adult populations with acute or episodic symptoms. Studies tracked patient-reported outcomes describing perceived discomfort and measuring the frequency and intensity of heartburn. These outcomes describing episodic or acute changes were primarily focused on measuring symptom intensity.

Because follow-up durations were limited, data characterizing the use of this agent as a primary, sustained therapy for long-term acid-related disorders remain insufficient. Furthermore, comparative evidence is lacking against newer classes of sustained acid-suppression agents (e.g., PPIs), which makes it difficult to contextualize the findings within the broader evidence landscape.

Evidence for Support in Chronic Functional Stress

Research relating to Diacart's use for support in chronic functional stress involves observational studies. This research was applied in studies examining patient-reported experiences in adults with conditions characterized by fluctuating or episodic manifestations. The evidence does not include data characterizing the effect on underlying disease markers or structural changes.

What is Still Uncertain About Diacart Research

The overall evidence landscape highlights several areas where more research is needed. In critical care, inconsistency in findings was observed in some studies regarding overall patient survival endpoints. Follow-up durations were limited across many studies, and the size and design of the evidence base varies across studies.

Key Studies & References

  1. Sodium Bicarbonate: MedlinePlus Drug Information (Antacid and Systemic Alkalizer)
  2. Sodium Bicarbonate Injection: MedlinePlus Drug Information (Metabolic Acidosis Treatment)

Frequently Asked Questions (FAQ)

Common questions about Diacart (FAQ)


Q: What is the main condition Diacart is officially approved to treat?

Official regulatory documents describe two distinct approved uses for the substance known as Diacart. It is approved for the correction of metabolic acidosis and for short-term relief of stomach acid symptoms (Sodium Bicarbonate component). It is also approved for the symptomatic treatment of osteoarthritis of the hip or knee (Diacerein component). The specific approved use is dependent on the prescribed formulation and indication.


Q: What are the known or researched benefits of Diacart besides its primary indication?

Studies and official information indicate that the Sodium Bicarbonate component is used for both systemic alkalinization (IV use) in specific medical settings and for antacid relief (oral use) for acute high stomach acid. The Diacerein component is specifically approved for treating osteoarthritis symptoms in the hip and knee joints.


Q: How long does it typically take for a patient to notice the expected effects of Diacart?

The onset of effect is dependent on the specific formulation and intended use. The antacid effect of the Sodium Bicarbonate component is generally rapid. When used for correcting metabolic acidosis, physiological improvement is typically measured within 1 to 2 days of starting therapy.


Q: How do health authorities generally describe the research evidence supporting Diacart?

The evidence base for the Sodium Bicarbonate component used in critical care has been described in studies as having inconsistency in findings regarding overall patient survival. Regulatory information for the Diacerein component restricts its use to a selected population due to regulatory concerns over potential serious side effects, such as liver toxicity and severe diarrhea.


Q: Is the role of Diacart to manage symptoms or to address the underlying cause of the condition?

Official information indicates that the Sodium Bicarbonate component used for metabolic acidosis is intended to help minimize risks associated with acidosis, while efforts to manage the underlying cause are addressed. When used as an antacid, its role is for symptom relief.


Q: Can Diacart be taken alongside over-the-counter supplements related to the condition it treats?

Official information indicates that the Sodium Bicarbonate component may interfere with the absorption of certain supplements, specifically multivitamins that contain iron. A time separation requirement is often specified for certain oral supplements to help ensure adequate absorption.


Q: Is Diacart classified as a preventative type of medication?

Official uses for the Sodium Bicarbonate component are primarily for the treatment of existing metabolic acidosis or symptom relief as an antacid. It is not generally described in official documents as a medication intended for general disease prevention.


Q: What are the most common side effects listed for Diacart?

According to official product information, common effects of the Sodium Bicarbonate component include thirst, stomach cramps, and gas. Common effects of the Diacerein component include diarrhea, loss of appetite, and intense yellow urine.


Q: Does Diacart commonly cause changes in weight or appetite?

Official information indicates that the Diacerein component is associated with loss of appetite as a common side effect. The Sodium Bicarbonate component is not typically associated with changes in weight.


Q: Are there any reported long-term safety concerns or side effects from years of using Diacart?

Official regulatory information addresses safety considerations for long-term use. For the Sodium Bicarbonate component, prolonged, high-dose use increases the risk of Milk-Alkali Syndrome and chronic electrolyte imbalance. Official documentation for the Diacerein component includes a regulatory requirement for regular liver function monitoring during long-term use.


Q: Is there a need to follow a tapering or gradual schedule when stopping Diacart?

Regulatory guidance for standard therapeutic doses does not typically specify a tapering schedule. However, official information notes that abrupt cessation of chronic, excessive use of the Sodium Bicarbonate component may potentially result in electrolyte disturbances.


Q: Is an allergic reaction to Diacart considered a common or rare event?

Hypersensitivity (an allergic reaction) to the drug's components is a listed contraindication in regulatory documents. However, the general frequency of occurrence for allergic reactions is often classified as not known in general clinical use.


Q: What kind of general effects are expected if a patient accidentally takes more Diacart than prescribed?

Taking too much of the Sodium Bicarbonate component can lead to serious electrolyte disturbances, such as the body's pH rising above normal (metabolic alkalosis) and elevated sodium levels (hypernatremia). In rare instances, excessive rapid gas formation can lead to severe gastrointestinal complications.


Q: Is it normal to experience a mild headache or slight nausea when first starting Diacart?

Official documentation lists headache and nausea as known side effects for both components. However, official information does not specifically label the experience of these symptoms when first starting treatment as 'normal.'


Q: Can Diacart affect sleep patterns or potentially cause insomnia?

Official product information indicates that both the Sodium Bicarbonate and Diacerein components can cause somnolence (drowsiness or sleepiness) or dizziness as a known side effect.


Q: Does Diacart interact with common over-the-counter pain relievers like acetaminophen or ibuprofen?

The Diacerein component may increase the hepatotoxic activities (potential for liver harm) of acetaminophen. The Sodium Bicarbonate component can affect the absorption of certain acidic drugs like salicylates (related to aspirin).


Q: Are there any specific foods, vitamins, or beverages that should be avoided when taking Diacart?

Official instructions advise that oral Sodium Bicarbonate should not be taken on an overly full stomach. Furthermore, the Diacerein component must be taken with meals to help minimize potential stomach upset and gastrointestinal side effects.


Q: Is it safe to consume alcohol while undergoing treatment with Diacart?

Official safety warnings indicate that combining the medicine with alcohol is associated with an increased risk of serious side effects and stomach problems.


Q: Does Diacart have known interactions with common herbal supplements like St. John's Wort?

Official documentation emphasizes the importance of disclosing all supplements and herbs to a health provider. This is because many medications, including the Sodium Bicarbonate component, can be affected by other orally administered substances.


Q: Does official guidance warn against driving or operating heavy machinery while taking Diacart?

Because the medicine can cause somnolence (drowsiness) and dizziness, official guidance advises that operating heavy machinery or driving may be unsafe if these effects are experienced.


Q: Does having high blood pressure or diabetes affect eligibility for Diacart?

The Sodium Bicarbonate component is sometimes used to treat acidosis that may occur in uncontrolled diabetes. However, due to its sodium content, it is cautioned or contraindicated for patients with heart failure or conditions at risk of fluid retention (which can relate to high blood pressure).


Q: How long does the body take to fully clear Diacart after the last use?

The elimination time varies between the components. The active metabolite of the Diacerein component has a mean elimination half-life of about 7 to 8 hours at steady state. The elimination time for the Sodium Bicarbonate component varies significantly based on individual kidney function.


Q: Why is Diacart available in different strengths or formulations?

Official information explains that different oral strengths and formulations of the Sodium Bicarbonate component are used to achieve different treatment effects. These uses range from a rapid antacid effect to longer-term changes for urine alkalinization.


Q: Is Diacart described as an anti-inflammatory agent or a different class of medicine?

The medicine contains two substances with different classifications. The Sodium Bicarbonate component is officially classified as an Alkalinizing Agent and Antacid. The Diacerein component is a symptomatic slow-acting drug in osteoarthritis ( SYSADOA) that is documented to have anti-inflammatory properties on cartilage.


Q: Why do official materials emphasize the importance of consistent use of Diacart?

Consistent use is emphasized in official instructions to ensure the treatment is effective and to obtain maximum relief of symptoms. For managing acid-base levels, the benefits rely on the regular timing of doses.


Q: Do official instructions provide general guidance on what to do about a missed dose of Diacart?

Official instructions provide general guidance for managing a missed dose. Instructions for managing a missed dose usually specify a limited time window for administering the dose. If this time is missed, the dose is typically skipped to maintain the schedule. A key warning in official materials emphasizes that a double dose should not be taken to compensate for a missed dose.


Q: Is there any official guidance regarding the potential for dependence or habit-forming use with Diacart?

Official guidance notes that while the substance itself is not commonly listed as habit-forming, some similar CNS-acting medications have a history of drug abuse or dependence. Patients are advised to use caution with all medications as directed.


Q: Where can a patient obtain an official Medication Guide or full Patient Information Leaflet for Diacart?

Patients can contact the U.S. Food and Drug Administration (FDA) or visit the FDA website to obtain official drug information and guides. Official patient information leaflets are also often available from the dispensing pharmacy.

How should Diacart be stored and disposed of?

Official Storage and Disposal Requirements

Storing Diacart (Sodium Bicarbonate) according to regulatory guidance is essential to maintain its stability and quality. The medicine must be kept at room temperature, typically between 15 C and 30 C (59 F and 86 F), and must be protected from both excess moisture and direct light.

Storage Restriction Requirement
Temperature Do not store above 30 C and keep from freezing
Packaging Store in the original container and keep it tightly closed
Child Safety Must be stored out of the sight and reach of children

For disposal, unused or expired Diacart should be discarded using a drug take-back program if available. If not, regulatory guidance permits mixing the medicine with an unappealing substance, sealing it in a plastic bag, and placing it in the household trash. It is important to avoid crushing the pills.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Diacart found in:

A-Z Index: